Vildagliptin
-
Molecular Structure
Detailed Description
Vildagliptin (previously identified as LAF237, trade names Zomelis, Galvus, cas 274901-16-5) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin (cas 274901-16-5) inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.Vildagliptin (cas 274901-16-5) has been shown to reduce hyperglycemia in type 2 diabetes mellitus.
View Contact Detail